palmitoylethanolamide.com.au
HomeResearchYuhang 2022

N-Acylethanolamine acid amidase (NAAA) exacerbates psoriasis inflammation by enhancing dendritic cell (DCs) maturation

Yuhang Li, Yitian Li, Sennan Xu, Yue Chen, Pan Zhou, Ting Hu, Hua Li, Ying Liu, Yaping Xu, Jie Ren, Yan Qiu, Canzhong Lu. Pharmacol Res. 2022 Nov:185:106491.

Laboratory studyHumansOther animals

Design
Laboratory study
Subjects
Psoriasis patients' samples and imiquimod-induced psoriasis in mice, including NAAA transgenic and knockout mice
Dose used in the study
No palmitoylethanolamide was given; the NAAA inhibitor F96 was applied locally, dose not stated in the abstract
Duration
Not stated in the abstract
What was measured
NAAA expression in psoriasis; psoriasis development with NAAA overexpression, deletion or inhibition; dendritic cell maturation; PEA-PPAR-alpha signalling, p65 acetylation and IL-10 production.

What the authors reported

The study found:

  • NAAA was raised in psoriasis patients and in the mouse model.
  • NAAA overexpression sped up psoriasis, while NAAA deletion or the inhibitor F96 lessened it, with NAAA in dendritic cells, not other cell types, driving the effect.
  • NAAA degraded PEA, reducing PEA-PPAR-alpha signalling, lowering IL-10 and promoting dendritic cell maturation.

Limits of this study

A mouse and tissue study; it cannot show effect in people treated in practice. PEA was not given. Several authors are co-inventors on patents covering NAAA inhibitors.

Source

PubMed 36244543 · doi:10.1016/j.phrs.2022.106491

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.